MCTA
- MCTA enabled African institutions and scholars to participate fully in the development of new tools for addressing malaria and in conducting interventions against malaria, and created a long-term partnership between African and Northern institutionsfrican-led institution
- Initially, MCTA worked in partnership with two other Gates Foundation grantees, the Malaria Vaccine Initiative (MVI) and the Medicines for Malaria Venture(MMV), to train personnel and improve facilities and infrastructure to ensure the successful execution of clinical trials in 10 countries across Africa (Mozambique, Gabon, Tanzania, Nigeria, Malawi, Burkina Faso, Ghana, The Gambia, Kenya and Senegal) where trial sites were identified for participation or are already participating in clinical trials.
- The long term objective was to identify, support, strengthen, mentor and network trial sites to facilitate their self-sustainability, ensuring that trial sites remain functional after the end of a trial and thus increasing the number of sites in Africa which should be ready to conduct trials for malaria vaccine and drug interventions.
- MCTA ensured that the trial sites were equipped with proper management, the tools to identify, hire and train staff, database and communications systems and transparent financial systems.